Press Release | Tue Apr 23, 2013 6:00am EDT

Achillion Announces Updated Phase 2 Results Including Early Sustained Virologic Response on ACH-3102 Plus Ribavirin in Genotype 1b Treatment-Naive Hepatitis C Patients

* Reuters is not responsible for the content in this press release.